Gaurang Brahmbhatt, MD
Family Medicine · Hoboken, NJNPI 1225204266
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,332 of the $88,935 with a category attached, or 81.3%. 27 manufacturers reported payments, led by Gilead at 57.3% of the total. Reporting peaked in 2019 at $35,377 and has fallen 98.8% since, to $422 in 2025. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $268.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$51K
- Viiv Healthcare Company$35K
- Modernatx, Inc.$1K
- Johnson & Johnson$366
- Merck$234
- Amarin Pharma, Inc.$218
- plus $1K from 21 others
Across 125 payments — averaging $20,445 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.5M
- GSK$580K
- Adaptive Biotechnologies Corporation$225K
- Genentech, Inc.$94K
- Visby Medical, Inc.$59K
- Amgen$40K
- plus $55K from 3 others
What the payments were for
- Consulting fees$3,1404%
- Speaking & faculty fees$72,33281%
- Travel & lodging$7,4798%
- Food & beverage$5,7656%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 161 | $50,934 |
| Viiv Healthcare Company | 65 | $34,664 |
| Modernatx, Inc. | 4 | $1,398 |
| Johnson & Johnson(2 entities) | 27 | $366 |
| Merck | 10 | $234 |
| Amarin Pharma, Inc. | 4 | $218 |
| Janssen Products, LP | 2 | $200 |
| GSK | 11 | $197 |
| Novo Nordisk | 5 | $118 |
| Napo Pharmaceuticals Inc | 8 | $107 |
| Daiichi Sankyo Inc. | 5 | $71 |
| Medtronic | 4 | $69 |
| Theratechnologies Inc. | 4 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Dynavax Technologies Corporation | 3 | $35 |
| Pfizer | 2 | $28 |
| AbbVie | 2 | $28 |
| Genentech USA, Inc. | 2 | $25 |
| Exact Sciences | 1 | $21 |
| Welch Allyn | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,935 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 68 | $276,542 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $82,346 |
| TivicayDolutegravir Sodium | 27 | $60,084 |
| PrezcobixDarunavir/Cobicistat | 13 | $39,459 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $18,254 |
| Darunavir | 13 | $14,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,901 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,307 |
| Ritonavir | 14 | $838 |
| Atorvastatin Calcium | 97 | $817 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $774 |
| Metoprolol Succinate | 29 | $379 |
| Omeprazole | 20 | $274 |
| FenofibrateFenofibrate Nanocrystallized | 15 | $222 |
| Rosuvastatin Calcium | 36 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $50,934 | $276,54268 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $34,664 | $142,43056 claims |
| Johnson & JohnsonPrezcobix | $366 | $39,45913 claims |
| MerckJanumet | $234 | $18,25420 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $197 | $12,20825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hoboken
- Juan LatorreHoboken$71K
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Sally MravcakJersey City$64K
- Louis TsarouhasLawrenceville$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.